Atossa Genetics - Multiple opportunities to address breast health
Atossa Genetics’s endoxifen programs are advancing in their respective breast health programs. The firm recently reported positive safety data from its Phase I study on topical endoxifen in men, and it completed enrolment for its Phase II endoxifen study in women with elevated mammographic breast density (MBD). It is also advancing an oral endoxifen formulation in women refractory to tamoxifen, and is applying its intraductal microcatheter (IDMC) with cancer drug fulvestrant. Our rNPV-derived equity valuation is $23.9m, or $3.66 per share.Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company's primary program is the development of Endoxifen, which is an active metabolite of tamoxifen to treat and prevent breast cancer. The company is developing an oral and topical form of Endoxifen. The company's Endoxifen is being developed to potentially treat a number of conditions, including: mammographic breast density; breast cancer in the window of opportunity between diagnosis of breast cancer and surgery; gynecomastia, which is male breast enlargement; and the recurrence of breast cancer.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.